Efficacy and tolerability of fixed, low-dose combination therapy with verapamil sustained-release and trandolapril in patients with mild to severe essential hypertension uncontrolled by monotherapy: An open-label, multicenter trial

Abstract

Background: Only 40% to 60% of patients with essential hypertension respond adequately to antihypertensive monotherapy. The combination of an angiotensin-converting enzyme inhibitor and a calcium antagonist, both of which have tissue-protective properties but different mechanisms of action, may lead to an additive antihypertensive effect.